Five major pharma firms break ABPI code of conduct, according to watchdog
pharmafile | December 15, 2016 | News story | Medical Communications, Sales and Marketing | ABPI, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Grunenthal, Janssen
Eli Lilly, Boehgringer Ingelheim, AstraZeneca UK, Grunenthal and Janssen-Cilag have been “named and shamed” by the Prescription Medicines Code of Practice Authority (PMCPA) for breaching Association of British Pharmaceutical Industry (ABPI) codes of conduct.
The PMCPA detailed each company’s wrongdoings in a statement on their website; all companies were targeted for “bringing discredit upon, and reducing confidence in, the pharmaceutical industry”, among a range of other company-specific transgressions. They are as follows:
Grunenthal was accused of “failing to comply with its previous undertaking”, failing to adequately brief reps over call rates and failing to agree written contracts before engaging health professionals.
Janssen was named for having sent uncertified materials from its European group to the UK promoting its drug Stelara (ustekinumab) for an unlicensed indication. The company voluntarily admitted these breaches.
AstraZeneca were also accused of promoting a misleading picture of the indication of its product Duaklir Genuair (formoterol/aclidinium) via uncertified presentations and independent speakers.
Despite an appeal, Eli Lilly and Boehringer Ingelheim were jointly named for misleading the market through the distribution of a letter which purported that Jardiance (empagliflozin) was to receive a license extension.The breach was highlighted by Janssen who argued the letter was a veiled marketing tool promoting the drug.
Lilly itself was also accused of the distribution of a publication which erroneously reported the dose of Vitamin B12 required to be supplied with Alimta (pemetrexed).
Matt Fellows
Related Content
Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity
Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated …
AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer
AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that …
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …
